IP Library Granted Patent US 9,629,848
Granted Patent B2
US 9,629,848 · App. 14/119,926 · Granted Apr 25, 2017

Compounds that modulate autoimmunity and methods of using the same

Inventors: George Eisenbarth (Golden, CO); Aaron Michels (Aurora, CO); Maki Nakayama (Denver, CO); David Ostrov (Gainesville, FL)
Assignees: The Regents of the University of Colorado, a body corporate; The University of Florida Research Foundation Incorporated
A61K31/53A61K31/155A61K31/195A61K31/221A61K31/397A61K31/4164A61K31/427A61K31/4409A61K31/495A61K31/519A61K31/64A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,629,848
App. No.
14/119,926
Granted
Apr 25, 2017
Kind
B2
Abstract

The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.

Claims (17)

1. A method of preventing, treating or ameliorating autoimmune diabetes by administering to a mammal in need of such treatment, a therapeutically effective amount of a compound selected from the group consisting of:

1,3,6,8-tetraazatricyclo[4.4.1.1(3,8)]dodecane,

1-ethyl-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-allyl-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-(15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]dec-1-yl)acetone,

1-(2,4,5-trichlorobenzyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-bromo-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

2-(15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]dec-1-yl)ethanol,

1-(4-chloro-2-butenyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-(2-chloro-2-propenyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-benzyl-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-(2,3-dibromo-2-propenyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

1-(3-chloro-2-propenyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane, and

1-(2-oxiranylmethyl)-15,3,5,7-tetraazatricyclo[3.3.1.1(3,7)]decane,

and pharmaceutically-acceptable salts thereof.

2. A method of treating autoimmune diabetes, or ameliorating symptoms of autoimmune diabetes, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a combination of at least one of the compounds of claim 1 and one or more other known anti-diabetic or anti-inflammatory or anti-celiac disease compounds.

3. The method of claim 2 , wherein the other anti-diabetic compound is at least one of an alpha-glucosidase inhibitor, a biguanide, a Dpp-4 inhibitor, a meglitinide, a sulfonylurea, a thiazolidinedione or combinations thereof.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 7, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047032/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2016
From: OSTROV, DAVID
To: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED
Reel/Frame 038225/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: EISENBARTH, GEORGE; MICHELS, AARON; NAKAYAMA, MAKI
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 037922/0093 →
Continuity (3)
Provisional Application 61490417 · May 26, 2011
Provisional Application 61580188 · Dec 23, 2011
Related Publication 20150038480A1 · Feb 5, 2015